ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.80, $0.14 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $57.3 million versus the consensus estimate of $54.27 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.